Stock Market Reviews

BNTX (BioNTech SE) News

Get the latest news, insights, and market updates on BNTX (BioNTech SE). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• BioNTech SE Reported A Surprise Loss, And Analysts Have Updated Their Forecasts
  As you might know, BioNTech SE ( NASDAQ:BNTX ) recently reported its quarterly numbers. Revenues of €1.5b beat...
  Nov 6, 2025 - $BNTX
• Nucleic Acid Therapeutics Market Report 2025: Competition Intensifies as Pfizer, Sanofi, Novartis, Moderna, BioNTech Expand Antisense and RNA Platform Innovations - Long-term Forecast to 2029 & 2034
  The nucleic acid therapeutics market is growing due to rising genetic and chronic disease prevalence, expanding genomics R&D, and increased RNA therapeutics adoption. Key opportunities include precision medicine demand, mRNA applications, advanced delivery platforms, AI integration, and regulatory support. Nucleic Acid Therapeutics Market Nucleic Acid Therapeutics Market Dublin, Nov. 05, 2025 (GLOBE NEWSWIRE) -- The "Nucleic Acid Therapeutics Market Report 2025" has been added to ResearchAndMark
  Nov 5, 2025 - $BNTX
• BioNTech (BNTX) Losses Worsen 22.1% Annually, Challenging Bullish Valuation Narratives
  BioNTech (NasdaqGS:BNTX) remains unprofitable, with losses worsening at an average rate of 22.1% per year over the last five years. While revenue is forecast to grow at just 1.7% per year, this trails the broader US market’s 10.5% annual average. The company’s price-to-sales ratio sits at 7.5x, which is well above peer averages but below the sector’s 11.3x. With profit margins showing no sign of improvement and ongoing unprofitability expected over the next three years, the share price trades...
  Nov 4, 2025 - $BNTX
• BioNTech SE (BNTX) Q3 2025 Earnings Call Highlights: Revenue Growth Amid Strategic Investments
  BioNTech SE (BNTX) reports increased revenues and strategic advancements despite a net loss, as it focuses on oncology and AI-driven therapies.
  Nov 3, 2025 - $BNTX
• Stocks Gain Pre-Bell as Traders Eye Strong Start to November, Await More Earnings
  The benchmark US stock measures were tracking in the green before the opening bell Monday as traders
  Nov 3, 2025 - $BNTX
• BioNTech Announces Third Quarter 2025 Financial Results and Corporate Update
  Continued clinical execution of oncology strategy with focus on two pan-tumor programs, including combination approaches to address the full continuum of cancer from early to late disease stagesDemonstrated encouraging anti-tumor activity and manageable safety profile of pumitamig (BNT327/BMS986545), a bispecific antibody candidate targeting PD-L11 and VEGF-A, in first disclosed interim data from global Phase 2 trial in extensive-stage small cell lung cancer Plan to initiate additional pivotal t
  Nov 3, 2025 - $BNTX
• European Equities Close Little Changed in Monday Trading; Eurozone Manufacturing Continues to Expand
  European stock markets closed little changed in Monday trading as the Stoxx Europe edged 0.07% highe
  Nov 3, 2025 - $BNTX
• Will BioNTech's (BNTX) Latest R&D Day Reveal a Shift in Its Innovation Ambitions?
  BioNTech recently announced it hosted its Innovation Series R&D Day on November 11, 2025, offering an in-depth update on its strategy and clinical pipeline via a public webcast, with replay and presentation slides accessible on its Investor Relations website. This event stands out as it provides investors and analysts a unique opportunity to directly hear from company leadership about BioNTech's latest pipeline developments and long-term vision. We'll examine how direct insights from...
  Nov 2, 2025 - $BNTX
• European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading
  European equities traded in the US as American depositary receipts were modestly lower late Friday m
  Oct 31, 2025 - $BNTX
• Singapore Approves Latest Pfizer/BioNTech COVID-19 Vaccine for All Ages
  Pfizer Inc. (NYSE:PFE) is one of the most undervalued large cap stocks to buy right now. On October 24, Pfizer Singapore and BioNTech (NASDAQ:BNTX) announced that the Health Sciences Authority/HSA of Singapore approved their LP.8.1-adapted monovalent COVID-19 vaccine (COMIRNATY LP.8.1; COVID-19 Vaccine, mRNA). The approval makes Singapore the first country in Southeast Asia to fully […]
  Oct 30, 2025 - $BNTX